nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—SRC—urinary bladder cancer	0.299	1	CbGaD
Crizotinib—AURKA—Epirubicin—urinary bladder cancer	0.168	0.545	CbGbCtD
Crizotinib—AURKA—Doxorubicin—urinary bladder cancer	0.0891	0.289	CbGbCtD
Crizotinib—ABCB1—Mitomycin—urinary bladder cancer	0.0173	0.0561	CbGbCtD
Crizotinib—CYP3A4—Thiotepa—urinary bladder cancer	0.00784	0.0255	CbGbCtD
Crizotinib—CYP3A5—Etoposide—urinary bladder cancer	0.00545	0.0177	CbGbCtD
Crizotinib—ABCB1—Gemcitabine—urinary bladder cancer	0.00497	0.0162	CbGbCtD
Crizotinib—ABCB1—Cisplatin—urinary bladder cancer	0.00361	0.0117	CbGbCtD
Crizotinib—ABCB1—Etoposide—urinary bladder cancer	0.00355	0.0115	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—urinary bladder cancer	0.00242	0.00786	CbGbCtD
Crizotinib—ABCB1—Methotrexate—urinary bladder cancer	0.00234	0.00762	CbGbCtD
Crizotinib—CYP3A4—Etoposide—urinary bladder cancer	0.00213	0.00691	CbGbCtD
Crizotinib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00145	0.00471	CbGbCtD
Crizotinib—PTK2—seminal vesicle—urinary bladder cancer	0.000395	0.00316	CbGeAlD
Crizotinib—TBK1—seminal vesicle—urinary bladder cancer	0.000395	0.00316	CbGeAlD
Crizotinib—TYK2—seminal vesicle—urinary bladder cancer	0.000392	0.00314	CbGeAlD
Crizotinib—EPHB6—prostate gland—urinary bladder cancer	0.000389	0.00311	CbGeAlD
Crizotinib—EPHA6—female reproductive system—urinary bladder cancer	0.000385	0.00308	CbGeAlD
Crizotinib—JAK3—female reproductive system—urinary bladder cancer	0.000385	0.00308	CbGeAlD
Crizotinib—MERTK—urethra—urinary bladder cancer	0.000385	0.00308	CbGeAlD
Crizotinib—PLK4—female reproductive system—urinary bladder cancer	0.000381	0.00304	CbGeAlD
Crizotinib—RPS6KB1—seminal vesicle—urinary bladder cancer	0.00038	0.00304	CbGeAlD
Crizotinib—ACVR1—renal system—urinary bladder cancer	0.00038	0.00304	CbGeAlD
Crizotinib—TAOK2—vagina—urinary bladder cancer	0.000379	0.00303	CbGeAlD
Crizotinib—STK4—female reproductive system—urinary bladder cancer	0.000378	0.00303	CbGeAlD
Crizotinib—FGR—seminal vesicle—urinary bladder cancer	0.000378	0.00302	CbGeAlD
Crizotinib—YES1—prostate gland—urinary bladder cancer	0.000376	0.00301	CbGeAlD
Crizotinib—MAP3K12—urethra—urinary bladder cancer	0.000373	0.00298	CbGeAlD
Crizotinib—ACVR1—urethra—urinary bladder cancer	0.000373	0.00298	CbGeAlD
Crizotinib—STK10—prostate gland—urinary bladder cancer	0.000372	0.00298	CbGeAlD
Crizotinib—TAOK3—prostate gland—urinary bladder cancer	0.000371	0.00297	CbGeAlD
Crizotinib—RIPK2—epithelium—urinary bladder cancer	0.00037	0.00296	CbGeAlD
Crizotinib—SLK—seminal vesicle—urinary bladder cancer	0.000362	0.0029	CbGeAlD
Crizotinib—SRC—prostate gland—urinary bladder cancer	0.000361	0.00289	CbGeAlD
Crizotinib—EPHB4—seminal vesicle—urinary bladder cancer	0.000359	0.00288	CbGeAlD
Crizotinib—PTK2B—smooth muscle tissue—urinary bladder cancer	0.000359	0.00287	CbGeAlD
Crizotinib—ALK—female reproductive system—urinary bladder cancer	0.000357	0.00286	CbGeAlD
Crizotinib—TYRO3—female reproductive system—urinary bladder cancer	0.000357	0.00286	CbGeAlD
Crizotinib—FER—female reproductive system—urinary bladder cancer	0.000357	0.00286	CbGeAlD
Crizotinib—JAK2—seminal vesicle—urinary bladder cancer	0.000357	0.00286	CbGeAlD
Crizotinib—EPHA2—seminal vesicle—urinary bladder cancer	0.000353	0.00282	CbGeAlD
Crizotinib—BMPR1B—female reproductive system—urinary bladder cancer	0.00035	0.0028	CbGeAlD
Crizotinib—MAP3K19—female reproductive system—urinary bladder cancer	0.00035	0.0028	CbGeAlD
Crizotinib—DCLK1—vagina—urinary bladder cancer	0.000346	0.00277	CbGeAlD
Crizotinib—PTK2B—renal system—urinary bladder cancer	0.000346	0.00277	CbGeAlD
Crizotinib—MAP3K3—seminal vesicle—urinary bladder cancer	0.000344	0.00275	CbGeAlD
Crizotinib—MAP4K5—seminal vesicle—urinary bladder cancer	0.000344	0.00275	CbGeAlD
Crizotinib—TNK2—female reproductive system—urinary bladder cancer	0.000343	0.00275	CbGeAlD
Crizotinib—IGF1R—female reproductive system—urinary bladder cancer	0.000343	0.00275	CbGeAlD
Crizotinib—PTK2—epithelium—urinary bladder cancer	0.000343	0.00275	CbGeAlD
Crizotinib—MAP4K2—female reproductive system—urinary bladder cancer	0.000339	0.00271	CbGeAlD
Crizotinib—NEK9—lymph node—urinary bladder cancer	0.000337	0.0027	CbGeAlD
Crizotinib—RIPK2—urethra—urinary bladder cancer	0.000337	0.00269	CbGeAlD
Crizotinib—STK3—female reproductive system—urinary bladder cancer	0.000334	0.00267	CbGeAlD
Crizotinib—TIE1—female reproductive system—urinary bladder cancer	0.000334	0.00267	CbGeAlD
Crizotinib—PTK2—smooth muscle tissue—urinary bladder cancer	0.000331	0.00265	CbGeAlD
Crizotinib—RPS6KB1—epithelium—urinary bladder cancer	0.00033	0.00264	CbGeAlD
Crizotinib—EPHB6—seminal vesicle—urinary bladder cancer	0.000329	0.00263	CbGeAlD
Crizotinib—TYK2—smooth muscle tissue—urinary bladder cancer	0.000328	0.00263	CbGeAlD
Crizotinib—AURKA—female reproductive system—urinary bladder cancer	0.000326	0.0026	CbGeAlD
Crizotinib—EPHA4—urethra—urinary bladder cancer	0.000326	0.0026	CbGeAlD
Crizotinib—CSF1R—prostate gland—urinary bladder cancer	0.000324	0.0026	CbGeAlD
Crizotinib—IRAK1—smooth muscle tissue—urinary bladder cancer	0.000324	0.00259	CbGeAlD
Crizotinib—FER—vagina—urinary bladder cancer	0.000323	0.00259	CbGeAlD
Crizotinib—EPHA5—vagina—urinary bladder cancer	0.000323	0.00259	CbGeAlD
Crizotinib—TESK1—female reproductive system—urinary bladder cancer	0.000323	0.00258	CbGeAlD
Crizotinib—TNK1—vagina—urinary bladder cancer	0.00032	0.00256	CbGeAlD
Crizotinib—PTK2—renal system—urinary bladder cancer	0.000318	0.00255	CbGeAlD
Crizotinib—TBK1—renal system—urinary bladder cancer	0.000318	0.00255	CbGeAlD
Crizotinib—RPS6KB1—smooth muscle tissue—urinary bladder cancer	0.000318	0.00254	CbGeAlD
Crizotinib—YES1—seminal vesicle—urinary bladder cancer	0.000318	0.00254	CbGeAlD
Crizotinib—MAP4K1—vagina—urinary bladder cancer	0.000317	0.00253	CbGeAlD
Crizotinib—TYK2—renal system—urinary bladder cancer	0.000316	0.00253	CbGeAlD
Crizotinib—AXL—smooth muscle tissue—urinary bladder cancer	0.000315	0.00252	CbGeAlD
Crizotinib—CYP3A4—urine—urinary bladder cancer	0.000314	0.00251	CbGeAlD
Crizotinib—TAOK3—seminal vesicle—urinary bladder cancer	0.000314	0.00251	CbGeAlD
Crizotinib—PTK2—urethra—urinary bladder cancer	0.000313	0.0025	CbGeAlD
Crizotinib—TBK1—urethra—urinary bladder cancer	0.000313	0.0025	CbGeAlD
Crizotinib—EPHB4—epithelium—urinary bladder cancer	0.000312	0.0025	CbGeAlD
Crizotinib—IGF1R—vagina—urinary bladder cancer	0.000311	0.00249	CbGeAlD
Crizotinib—TYK2—urethra—urinary bladder cancer	0.000311	0.00248	CbGeAlD
Crizotinib—JAK2—epithelium—urinary bladder cancer	0.00031	0.00248	CbGeAlD
Crizotinib—PRKD1—lymph node—urinary bladder cancer	0.000307	0.00246	CbGeAlD
Crizotinib—LIMK2—female reproductive system—urinary bladder cancer	0.000307	0.00246	CbGeAlD
Crizotinib—EPHA2—epithelium—urinary bladder cancer	0.000306	0.00245	CbGeAlD
Crizotinib—MAP4K2—vagina—urinary bladder cancer	0.000306	0.00245	CbGeAlD
Crizotinib—RPS6KB1—renal system—urinary bladder cancer	0.000306	0.00245	CbGeAlD
Crizotinib—MAP3K12—female reproductive system—urinary bladder cancer	0.000304	0.00243	CbGeAlD
Crizotinib—FLT3—female reproductive system—urinary bladder cancer	0.000304	0.00243	CbGeAlD
Crizotinib—ACVR1—female reproductive system—urinary bladder cancer	0.000304	0.00243	CbGeAlD
Crizotinib—LIMK1—lymph node—urinary bladder cancer	0.000303	0.00243	CbGeAlD
Crizotinib—STK3—vagina—urinary bladder cancer	0.000302	0.00242	CbGeAlD
Crizotinib—EPHB4—smooth muscle tissue—urinary bladder cancer	0.000301	0.00241	CbGeAlD
Crizotinib—RPS6KB1—urethra—urinary bladder cancer	0.000301	0.00241	CbGeAlD
Crizotinib—FGR—urethra—urinary bladder cancer	0.000299	0.00239	CbGeAlD
Crizotinib—LCK—urethra—urinary bladder cancer	0.000299	0.00239	CbGeAlD
Crizotinib—TEK—epithelium—urinary bladder cancer	0.000299	0.00239	CbGeAlD
Crizotinib—JAK2—smooth muscle tissue—urinary bladder cancer	0.000299	0.00239	CbGeAlD
Crizotinib—STK35—female reproductive system—urinary bladder cancer	0.000298	0.00238	CbGeAlD
Crizotinib—AXL—urethra—urinary bladder cancer	0.000298	0.00238	CbGeAlD
Crizotinib—PRKD3—lymph node—urinary bladder cancer	0.000296	0.00236	CbGeAlD
Crizotinib—AURKA—vagina—urinary bladder cancer	0.000294	0.00236	CbGeAlD
Crizotinib—TESK1—vagina—urinary bladder cancer	0.000292	0.00234	CbGeAlD
Crizotinib—EPHB4—renal system—urinary bladder cancer	0.00029	0.00232	CbGeAlD
Crizotinib—DSTYK—lymph node—urinary bladder cancer	0.000288	0.00231	CbGeAlD
Crizotinib—TEK—smooth muscle tissue—urinary bladder cancer	0.000288	0.0023	CbGeAlD
Crizotinib—MAP4K5—smooth muscle tissue—urinary bladder cancer	0.000288	0.0023	CbGeAlD
Crizotinib—JAK2—renal system—urinary bladder cancer	0.000288	0.0023	CbGeAlD
Crizotinib—BMP2K—female reproductive system—urinary bladder cancer	0.000287	0.00229	CbGeAlD
Crizotinib—SLK—urethra—urinary bladder cancer	0.000287	0.00229	CbGeAlD
Crizotinib—BLK—lymph node—urinary bladder cancer	0.000285	0.00228	CbGeAlD
Crizotinib—EPHB4—urethra—urinary bladder cancer	0.000285	0.00228	CbGeAlD
Crizotinib—IGF1R—Idarubicin—Valrubicin—urinary bladder cancer	0.000284	0.0649	CbGdCrCtD
Crizotinib—MERTK—vagina—urinary bladder cancer	0.000284	0.00227	CbGeAlD
Crizotinib—JAK2—urethra—urinary bladder cancer	0.000283	0.00226	CbGeAlD
Crizotinib—LTK—lymph node—urinary bladder cancer	0.000282	0.00226	CbGeAlD
Crizotinib—CASK—lymph node—urinary bladder cancer	0.000282	0.00226	CbGeAlD
Crizotinib—EPHA2—urethra—urinary bladder cancer	0.000279	0.00223	CbGeAlD
Crizotinib—LIMK2—vagina—urinary bladder cancer	0.000278	0.00222	CbGeAlD
Crizotinib—TEK—renal system—urinary bladder cancer	0.000277	0.00222	CbGeAlD
Crizotinib—NUAK2—vagina—urinary bladder cancer	0.000277	0.00222	CbGeAlD
Crizotinib—PTK2B—female reproductive system—urinary bladder cancer	0.000277	0.00221	CbGeAlD
Crizotinib—MAP3K12—vagina—urinary bladder cancer	0.000275	0.0022	CbGeAlD
Crizotinib—ACVR1—vagina—urinary bladder cancer	0.000275	0.0022	CbGeAlD
Crizotinib—RIPK2—female reproductive system—urinary bladder cancer	0.000275	0.0022	CbGeAlD
Crizotinib—CSF1R—seminal vesicle—urinary bladder cancer	0.000274	0.0022	CbGeAlD
Crizotinib—MAPK7—lymph node—urinary bladder cancer	0.000273	0.00218	CbGeAlD
Crizotinib—TXK—lymph node—urinary bladder cancer	0.000273	0.00218	CbGeAlD
Crizotinib—MAP3K3—urethra—urinary bladder cancer	0.000272	0.00218	CbGeAlD
Crizotinib—TEK—urethra—urinary bladder cancer	0.000272	0.00218	CbGeAlD
Crizotinib—MAP4K5—urethra—urinary bladder cancer	0.000272	0.00218	CbGeAlD
Crizotinib—FES—lymph node—urinary bladder cancer	0.00027	0.00216	CbGeAlD
Crizotinib—STK35—vagina—urinary bladder cancer	0.000269	0.00215	CbGeAlD
Crizotinib—YES1—smooth muscle tissue—urinary bladder cancer	0.000266	0.00213	CbGeAlD
Crizotinib—SRC—epithelium—urinary bladder cancer	0.000266	0.00212	CbGeAlD
Crizotinib—EPHA4—female reproductive system—urinary bladder cancer	0.000265	0.00212	CbGeAlD
Crizotinib—ABL2—vagina—urinary bladder cancer	0.000262	0.0021	CbGeAlD
Crizotinib—MAP3K2—female reproductive system—urinary bladder cancer	0.00026	0.00208	CbGeAlD
Crizotinib—EPHB6—urethra—urinary bladder cancer	0.00026	0.00208	CbGeAlD
Crizotinib—BMP2K—vagina—urinary bladder cancer	0.000259	0.00207	CbGeAlD
Crizotinib—ABL1—prostate gland—urinary bladder cancer	0.000256	0.00205	CbGeAlD
Crizotinib—YES1—renal system—urinary bladder cancer	0.000256	0.00205	CbGeAlD
Crizotinib—SRC—smooth muscle tissue—urinary bladder cancer	0.000256	0.00205	CbGeAlD
Crizotinib—MET—lymph node—urinary bladder cancer	0.000256	0.00205	CbGeAlD
Crizotinib—PTK2—female reproductive system—urinary bladder cancer	0.000255	0.00204	CbGeAlD
Crizotinib—TBK1—female reproductive system—urinary bladder cancer	0.000255	0.00204	CbGeAlD
Crizotinib—STK10—renal system—urinary bladder cancer	0.000254	0.00203	CbGeAlD
Crizotinib—TYK2—female reproductive system—urinary bladder cancer	0.000253	0.00203	CbGeAlD
Crizotinib—TAOK3—renal system—urinary bladder cancer	0.000253	0.00202	CbGeAlD
Crizotinib—YES1—urethra—urinary bladder cancer	0.000251	0.00201	CbGeAlD
Crizotinib—PTK2B—vagina—urinary bladder cancer	0.00025	0.002	CbGeAlD
Crizotinib—IRAK1—female reproductive system—urinary bladder cancer	0.00025	0.002	CbGeAlD
Crizotinib—RIPK2—vagina—urinary bladder cancer	0.000248	0.00199	CbGeAlD
Crizotinib—TAOK3—urethra—urinary bladder cancer	0.000248	0.00199	CbGeAlD
Crizotinib—CDK7—lymph node—urinary bladder cancer	0.000247	0.00198	CbGeAlD
Crizotinib—SRC—renal system—urinary bladder cancer	0.000246	0.00197	CbGeAlD
Crizotinib—TAOK2—lymph node—urinary bladder cancer	0.000245	0.00196	CbGeAlD
Crizotinib—RPS6KB1—female reproductive system—urinary bladder cancer	0.000245	0.00196	CbGeAlD
Crizotinib—FGR—female reproductive system—urinary bladder cancer	0.000244	0.00195	CbGeAlD
Crizotinib—AXL—female reproductive system—urinary bladder cancer	0.000243	0.00194	CbGeAlD
Crizotinib—EPHA4—vagina—urinary bladder cancer	0.00024	0.00192	CbGeAlD
Crizotinib—EPHA3—lymph node—urinary bladder cancer	0.000236	0.00189	CbGeAlD
Crizotinib—ACVR1B—lymph node—urinary bladder cancer	0.000236	0.00189	CbGeAlD
Crizotinib—EPHB4—female reproductive system—urinary bladder cancer	0.000232	0.00186	CbGeAlD
Crizotinib—TBK1—vagina—urinary bladder cancer	0.000231	0.00184	CbGeAlD
Crizotinib—PTK2—vagina—urinary bladder cancer	0.000231	0.00184	CbGeAlD
Crizotinib—JAK2—female reproductive system—urinary bladder cancer	0.00023	0.00184	CbGeAlD
Crizotinib—CSF1R—smooth muscle tissue—urinary bladder cancer	0.00023	0.00184	CbGeAlD
Crizotinib—CDK7—Daunorubicin—Valrubicin—urinary bladder cancer	0.000229	0.0523	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Valrubicin—urinary bladder cancer	0.000229	0.0523	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Valrubicin—urinary bladder cancer	0.000229	0.0523	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Valrubicin—urinary bladder cancer	0.000229	0.0523	CbGdCrCtD
Crizotinib—TYK2—vagina—urinary bladder cancer	0.000229	0.00183	CbGeAlD
Crizotinib—EPHA2—female reproductive system—urinary bladder cancer	0.000228	0.00182	CbGeAlD
Crizotinib—JAK3—lymph node—urinary bladder cancer	0.000225	0.0018	CbGeAlD
Crizotinib—DCLK1—lymph node—urinary bladder cancer	0.000224	0.00179	CbGeAlD
Crizotinib—PLK4—lymph node—urinary bladder cancer	0.000223	0.00178	CbGeAlD
Crizotinib—MAP4K5—female reproductive system—urinary bladder cancer	0.000222	0.00178	CbGeAlD
Crizotinib—TEK—female reproductive system—urinary bladder cancer	0.000222	0.00178	CbGeAlD
Crizotinib—MAP3K3—female reproductive system—urinary bladder cancer	0.000222	0.00178	CbGeAlD
Crizotinib—RPS6KB1—vagina—urinary bladder cancer	0.000222	0.00177	CbGeAlD
Crizotinib—STK4—lymph node—urinary bladder cancer	0.000221	0.00177	CbGeAlD
Crizotinib—FGR—vagina—urinary bladder cancer	0.00022	0.00176	CbGeAlD
Crizotinib—LCK—vagina—urinary bladder cancer	0.00022	0.00176	CbGeAlD
Crizotinib—AXL—vagina—urinary bladder cancer	0.00022	0.00176	CbGeAlD
Crizotinib—CSF1R—urethra—urinary bladder cancer	0.000217	0.00174	CbGeAlD
Crizotinib—ABL1—seminal vesicle—urinary bladder cancer	0.000217	0.00174	CbGeAlD
Crizotinib—SLK—vagina—urinary bladder cancer	0.000211	0.00169	CbGeAlD
Crizotinib—EPHB4—vagina—urinary bladder cancer	0.00021	0.00168	CbGeAlD
Crizotinib—FER—lymph node—urinary bladder cancer	0.000209	0.00167	CbGeAlD
Crizotinib—ALK—lymph node—urinary bladder cancer	0.000209	0.00167	CbGeAlD
Crizotinib—JAK2—vagina—urinary bladder cancer	0.000208	0.00167	CbGeAlD
Crizotinib—TNK1—lymph node—urinary bladder cancer	0.000207	0.00166	CbGeAlD
Crizotinib—EPHA2—vagina—urinary bladder cancer	0.000206	0.00165	CbGeAlD
Crizotinib—YES1—female reproductive system—urinary bladder cancer	0.000205	0.00164	CbGeAlD
Crizotinib—BMPR1B—lymph node—urinary bladder cancer	0.000205	0.00164	CbGeAlD
Crizotinib—MAP4K1—lymph node—urinary bladder cancer	0.000205	0.00164	CbGeAlD
Crizotinib—STK10—female reproductive system—urinary bladder cancer	0.000203	0.00163	CbGeAlD
Crizotinib—TAOK3—female reproductive system—urinary bladder cancer	0.000202	0.00162	CbGeAlD
Crizotinib—CASK—Teniposide—Etoposide—urinary bladder cancer	0.000202	0.0461	CbGdCrCtD
Crizotinib—IGF1R—lymph node—urinary bladder cancer	0.000201	0.00161	CbGeAlD
Crizotinib—TNK2—lymph node—urinary bladder cancer	0.000201	0.00161	CbGeAlD
Crizotinib—MAP4K5—vagina—urinary bladder cancer	0.000201	0.00161	CbGeAlD
Crizotinib—MAP3K3—vagina—urinary bladder cancer	0.000201	0.00161	CbGeAlD
Crizotinib—MAP4K2—lymph node—urinary bladder cancer	0.000198	0.00159	CbGeAlD
Crizotinib—SRC—female reproductive system—urinary bladder cancer	0.000197	0.00158	CbGeAlD
Crizotinib—TIE1—lymph node—urinary bladder cancer	0.000195	0.00156	CbGeAlD
Crizotinib—STK3—lymph node—urinary bladder cancer	0.000195	0.00156	CbGeAlD
Crizotinib—EPHB6—vagina—urinary bladder cancer	0.000192	0.00154	CbGeAlD
Crizotinib—AURKA—lymph node—urinary bladder cancer	0.00019	0.00152	CbGeAlD
Crizotinib—TESK1—lymph node—urinary bladder cancer	0.000189	0.00151	CbGeAlD
Crizotinib—YES1—vagina—urinary bladder cancer	0.000185	0.00148	CbGeAlD
Crizotinib—STK10—vagina—urinary bladder cancer	0.000184	0.00147	CbGeAlD
Crizotinib—MERTK—lymph node—urinary bladder cancer	0.000184	0.00147	CbGeAlD
Crizotinib—TAOK3—vagina—urinary bladder cancer	0.000183	0.00146	CbGeAlD
Crizotinib—ABL1—smooth muscle tissue—urinary bladder cancer	0.000182	0.00145	CbGeAlD
Crizotinib—Urethral disorder—Etoposide—urinary bladder cancer	0.00018	0.00181	CcSEcCtD
Crizotinib—LIMK2—lymph node—urinary bladder cancer	0.00018	0.00144	CbGeAlD
Crizotinib—Arrhythmia—Cisplatin—urinary bladder cancer	0.000179	0.0018	CcSEcCtD
Crizotinib—NUAK2—lymph node—urinary bladder cancer	0.000179	0.00143	CbGeAlD
Crizotinib—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000178	0.00179	CcSEcCtD
Crizotinib—Neuropathy—Doxorubicin—urinary bladder cancer	0.000178	0.00179	CcSEcCtD
Crizotinib—Sepsis—Epirubicin—urinary bladder cancer	0.000178	0.00179	CcSEcCtD
Crizotinib—MAP3K12—lymph node—urinary bladder cancer	0.000178	0.00142	CbGeAlD
Crizotinib—ACVR1—lymph node—urinary bladder cancer	0.000178	0.00142	CbGeAlD
Crizotinib—FLT3—lymph node—urinary bladder cancer	0.000178	0.00142	CbGeAlD
Crizotinib—Hepatic failure—Methotrexate—urinary bladder cancer	0.000177	0.00178	CcSEcCtD
Crizotinib—CSF1R—female reproductive system—urinary bladder cancer	0.000177	0.00142	CbGeAlD
Crizotinib—Skin disorder—Thiotepa—urinary bladder cancer	0.000177	0.00177	CcSEcCtD
Crizotinib—ABL1—renal system—urinary bladder cancer	0.000175	0.0014	CbGeAlD
Crizotinib—Malnutrition—Cisplatin—urinary bladder cancer	0.000175	0.00175	CcSEcCtD
Crizotinib—STK35—lymph node—urinary bladder cancer	0.000174	0.00139	CbGeAlD
Crizotinib—Vision blurred—Fluorouracil—urinary bladder cancer	0.000174	0.00174	CcSEcCtD
Crizotinib—Anaemia—Gemcitabine—urinary bladder cancer	0.000173	0.00174	CcSEcCtD
Crizotinib—Eye disorder—Etoposide—urinary bladder cancer	0.000172	0.00173	CcSEcCtD
Crizotinib—ABL1—urethra—urinary bladder cancer	0.000172	0.00137	CbGeAlD
Crizotinib—Blood alkaline phosphatase increased—Epirubicin—urinary bladder cancer	0.000171	0.00172	CcSEcCtD
Crizotinib—Cardiac disorder—Etoposide—urinary bladder cancer	0.000171	0.00171	CcSEcCtD
Crizotinib—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00017	0.00171	CcSEcCtD
Crizotinib—Anaemia—Fluorouracil—urinary bladder cancer	0.00017	0.00171	CcSEcCtD
Crizotinib—ABL2—lymph node—urinary bladder cancer	0.00017	0.00136	CbGeAlD
Crizotinib—Visual disturbance—Methotrexate—urinary bladder cancer	0.000168	0.00169	CcSEcCtD
Crizotinib—Leukopenia—Gemcitabine—urinary bladder cancer	0.000168	0.00168	CcSEcCtD
Crizotinib—BMP2K—lymph node—urinary bladder cancer	0.000168	0.00134	CbGeAlD
Crizotinib—Hepatic failure—Epirubicin—urinary bladder cancer	0.000166	0.00166	CcSEcCtD
Crizotinib—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000166	0.00166	CcSEcCtD
Crizotinib—Leukopenia—Fluorouracil—urinary bladder cancer	0.000165	0.00166	CcSEcCtD
Crizotinib—Sepsis—Doxorubicin—urinary bladder cancer	0.000165	0.00165	CcSEcCtD
Crizotinib—Vision blurred—Cisplatin—urinary bladder cancer	0.000165	0.00165	CcSEcCtD
Crizotinib—Paraesthesia—Thiotepa—urinary bladder cancer	0.000163	0.00164	CcSEcCtD
Crizotinib—PTK2B—lymph node—urinary bladder cancer	0.000162	0.0013	CbGeAlD
Crizotinib—Anaemia—Cisplatin—urinary bladder cancer	0.000161	0.00162	CcSEcCtD
Crizotinib—RIPK2—lymph node—urinary bladder cancer	0.000161	0.00129	CbGeAlD
Crizotinib—CSF1R—vagina—urinary bladder cancer	0.00016	0.00128	CbGeAlD
Crizotinib—Dyspepsia—Thiotepa—urinary bladder cancer	0.00016	0.00161	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Doxorubicin—urinary bladder cancer	0.000158	0.00159	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000158	0.00159	CcSEcCtD
Crizotinib—Decreased appetite—Thiotepa—urinary bladder cancer	0.000158	0.00159	CcSEcCtD
Crizotinib—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000158	0.00158	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000157	0.00158	CcSEcCtD
Crizotinib—Fatigue—Thiotepa—urinary bladder cancer	0.000157	0.00157	CcSEcCtD
Crizotinib—Dysgeusia—Etoposide—urinary bladder cancer	0.000157	0.00157	CcSEcCtD
Crizotinib—Leukopenia—Cisplatin—urinary bladder cancer	0.000156	0.00157	CcSEcCtD
Crizotinib—Constipation—Thiotepa—urinary bladder cancer	0.000155	0.00156	CcSEcCtD
Crizotinib—EPHA4—lymph node—urinary bladder cancer	0.000155	0.00124	CbGeAlD
Crizotinib—Hepatic failure—Doxorubicin—urinary bladder cancer	0.000153	0.00154	CcSEcCtD
Crizotinib—Oedema—Gemcitabine—urinary bladder cancer	0.000153	0.00154	CcSEcCtD
Crizotinib—MAP3K2—lymph node—urinary bladder cancer	0.000152	0.00122	CbGeAlD
Crizotinib—Infection—Gemcitabine—urinary bladder cancer	0.000152	0.00153	CcSEcCtD
Crizotinib—Oedema—Fluorouracil—urinary bladder cancer	0.00015	0.00151	CcSEcCtD
Crizotinib—CYP3A5—prostate gland—urinary bladder cancer	0.00015	0.0012	CbGeAlD
Crizotinib—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00015	0.00151	CcSEcCtD
Crizotinib—Infection—Fluorouracil—urinary bladder cancer	0.000149	0.0015	CcSEcCtD
Crizotinib—PLK4—Epirubicin—Valrubicin—urinary bladder cancer	0.000149	0.0341	CbGdCrCtD
Crizotinib—PLK4—Idarubicin—Valrubicin—urinary bladder cancer	0.000149	0.0341	CbGdCrCtD
Crizotinib—PLK4—Doxorubicin—Valrubicin—urinary bladder cancer	0.000149	0.0341	CbGdCrCtD
Crizotinib—PTK2—lymph node—urinary bladder cancer	0.000149	0.00119	CbGeAlD
Crizotinib—TBK1—lymph node—urinary bladder cancer	0.000149	0.00119	CbGeAlD
Crizotinib—Diplopia—Epirubicin—urinary bladder cancer	0.000149	0.0015	CcSEcCtD
Crizotinib—Skin disorder—Gemcitabine—urinary bladder cancer	0.000149	0.00149	CcSEcCtD
Crizotinib—TYK2—lymph node—urinary bladder cancer	0.000148	0.00119	CbGeAlD
Crizotinib—Anaemia—Etoposide—urinary bladder cancer	0.000148	0.00149	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000148	0.00148	CcSEcCtD
Crizotinib—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000147	0.00148	CcSEcCtD
Crizotinib—IRAK1—lymph node—urinary bladder cancer	0.000146	0.00117	CbGeAlD
Crizotinib—Face oedema—Epirubicin—urinary bladder cancer	0.000144	0.00144	CcSEcCtD
Crizotinib—Body temperature increased—Thiotepa—urinary bladder cancer	0.000144	0.00144	CcSEcCtD
Crizotinib—RPS6KB1—lymph node—urinary bladder cancer	0.000143	0.00115	CbGeAlD
Crizotinib—Leukopenia—Etoposide—urinary bladder cancer	0.000143	0.00144	CcSEcCtD
Crizotinib—FGR—lymph node—urinary bladder cancer	0.000143	0.00114	CbGeAlD
Crizotinib—LCK—lymph node—urinary bladder cancer	0.000143	0.00114	CbGeAlD
Crizotinib—Oedema—Cisplatin—urinary bladder cancer	0.000143	0.00143	CcSEcCtD
Crizotinib—AXL—lymph node—urinary bladder cancer	0.000142	0.00114	CbGeAlD
Crizotinib—Infection—Cisplatin—urinary bladder cancer	0.000142	0.00142	CcSEcCtD
Crizotinib—Loss of consciousness—Etoposide—urinary bladder cancer	0.000141	0.00141	CcSEcCtD
Crizotinib—ABL1—female reproductive system—urinary bladder cancer	0.00014	0.00112	CbGeAlD
Crizotinib—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00014	0.0014	CcSEcCtD
Crizotinib—Skin disorder—Cisplatin—urinary bladder cancer	0.000138	0.00139	CcSEcCtD
Crizotinib—Diplopia—Doxorubicin—urinary bladder cancer	0.000138	0.00138	CcSEcCtD
Crizotinib—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000137	0.00138	CcSEcCtD
Crizotinib—SLK—lymph node—urinary bladder cancer	0.000137	0.00109	CbGeAlD
Crizotinib—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000136	0.00137	CcSEcCtD
Crizotinib—EPHB4—lymph node—urinary bladder cancer	0.000136	0.00109	CbGeAlD
Crizotinib—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000136	0.00136	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000135	0.00136	CcSEcCtD
Crizotinib—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000135	0.00136	CcSEcCtD
Crizotinib—JAK2—lymph node—urinary bladder cancer	0.000135	0.00108	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000134	0.00135	CcSEcCtD
Crizotinib—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000134	0.00135	CcSEcCtD
Crizotinib—EPHA2—lymph node—urinary bladder cancer	0.000133	0.00107	CbGeAlD
Crizotinib—Face oedema—Doxorubicin—urinary bladder cancer	0.000133	0.00134	CcSEcCtD
Crizotinib—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000133	0.00134	CcSEcCtD
Crizotinib—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000132	0.00133	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000132	0.00133	CcSEcCtD
Crizotinib—Fatigue—Gemcitabine—urinary bladder cancer	0.000132	0.00132	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000131	0.00132	CcSEcCtD
Crizotinib—Muscular weakness—Epirubicin—urinary bladder cancer	0.000131	0.00132	CcSEcCtD
Crizotinib—Constipation—Gemcitabine—urinary bladder cancer	0.000131	0.00131	CcSEcCtD
Crizotinib—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000131	0.00131	CcSEcCtD
Crizotinib—Asthenia—Thiotepa—urinary bladder cancer	0.00013	0.00131	CcSEcCtD
Crizotinib—MAP4K5—lymph node—urinary bladder cancer	0.00013	0.00104	CbGeAlD
Crizotinib—TEK—lymph node—urinary bladder cancer	0.00013	0.00104	CbGeAlD
Crizotinib—MAP3K3—lymph node—urinary bladder cancer	0.00013	0.00104	CbGeAlD
Crizotinib—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00013	0.0013	CcSEcCtD
Crizotinib—Infection—Etoposide—urinary bladder cancer	0.00013	0.0013	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—urinary bladder cancer	0.000129	0.00129	CcSEcCtD
Crizotinib—Paraesthesia—Cisplatin—urinary bladder cancer	0.000128	0.00129	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000128	0.00128	CcSEcCtD
Crizotinib—Dyspnoea—Cisplatin—urinary bladder cancer	0.000127	0.00128	CcSEcCtD
Crizotinib—Skin disorder—Etoposide—urinary bladder cancer	0.000127	0.00127	CcSEcCtD
Crizotinib—ABL1—vagina—urinary bladder cancer	0.000127	0.00101	CbGeAlD
Crizotinib—ABL1—Doxorubicin—Valrubicin—urinary bladder cancer	0.000125	0.0287	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Valrubicin—urinary bladder cancer	0.000125	0.0287	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Valrubicin—urinary bladder cancer	0.000125	0.0287	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Valrubicin—urinary bladder cancer	0.000125	0.0287	CbGdCrCtD
Crizotinib—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000125	0.00126	CcSEcCtD
Crizotinib—Diarrhoea—Thiotepa—urinary bladder cancer	0.000124	0.00125	CcSEcCtD
Crizotinib—EPHB6—lymph node—urinary bladder cancer	0.000124	0.000993	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000124	0.00125	CcSEcCtD
Crizotinib—Decreased appetite—Cisplatin—urinary bladder cancer	0.000124	0.00124	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—urinary bladder cancer	0.000123	0.00124	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000123	0.00124	CcSEcCtD
Crizotinib—Infestation—Methotrexate—urinary bladder cancer	0.000123	0.00123	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—urinary bladder cancer	0.000123	0.00123	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000122	0.00122	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000122	0.00122	CcSEcCtD
Crizotinib—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000121	0.00121	CcSEcCtD
Crizotinib—Neutropenia—Epirubicin—urinary bladder cancer	0.00012	0.00121	CcSEcCtD
Crizotinib—Dizziness—Thiotepa—urinary bladder cancer	0.00012	0.00121	CcSEcCtD
Crizotinib—YES1—lymph node—urinary bladder cancer	0.00012	0.00096	CbGeAlD
Crizotinib—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00012	0.0012	CcSEcCtD
Crizotinib—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000119	0.00119	CcSEcCtD
Crizotinib—STK10—lymph node—urinary bladder cancer	0.000119	0.000951	CbGeAlD
Crizotinib—TAOK3—lymph node—urinary bladder cancer	0.000118	0.000947	CbGeAlD
Crizotinib—Paraesthesia—Etoposide—urinary bladder cancer	0.000117	0.00118	CcSEcCtD
Crizotinib—AURKA—Epirubicin—Valrubicin—urinary bladder cancer	0.000117	0.0267	CbGdCrCtD
Crizotinib—AURKA—Doxorubicin—Valrubicin—urinary bladder cancer	0.000117	0.0267	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Valrubicin—urinary bladder cancer	0.000117	0.0267	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Valrubicin—urinary bladder cancer	0.000117	0.0267	CbGdCrCtD
Crizotinib—Weight decreased—Epirubicin—urinary bladder cancer	0.000116	0.00117	CcSEcCtD
Crizotinib—Dyspnoea—Etoposide—urinary bladder cancer	0.000116	0.00117	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000116	0.00117	CcSEcCtD
Crizotinib—Vomiting—Thiotepa—urinary bladder cancer	0.000116	0.00116	CcSEcCtD
Crizotinib—Pneumonia—Epirubicin—urinary bladder cancer	0.000115	0.00116	CcSEcCtD
Crizotinib—SRC—lymph node—urinary bladder cancer	0.000115	0.000923	CbGeAlD
Crizotinib—Infestation—Epirubicin—urinary bladder cancer	0.000115	0.00115	CcSEcCtD
Crizotinib—Infestation NOS—Epirubicin—urinary bladder cancer	0.000115	0.00115	CcSEcCtD
Crizotinib—Rash—Thiotepa—urinary bladder cancer	0.000115	0.00115	CcSEcCtD
Crizotinib—Dermatitis—Thiotepa—urinary bladder cancer	0.000115	0.00115	CcSEcCtD
Crizotinib—Decreased appetite—Etoposide—urinary bladder cancer	0.000114	0.00114	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000113	0.00113	CcSEcCtD
Crizotinib—Body temperature increased—Cisplatin—urinary bladder cancer	0.000113	0.00113	CcSEcCtD
Crizotinib—Fatigue—Etoposide—urinary bladder cancer	0.000113	0.00113	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000113	0.00113	CcSEcCtD
Crizotinib—Constipation—Etoposide—urinary bladder cancer	0.000112	0.00112	CcSEcCtD
Crizotinib—Neutropenia—Doxorubicin—urinary bladder cancer	0.000111	0.00112	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000111	0.00111	CcSEcCtD
Crizotinib—Asthenia—Gemcitabine—urinary bladder cancer	0.00011	0.0011	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000109	0.00109	CcSEcCtD
Crizotinib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000109	0.00109	CcSEcCtD
Crizotinib—Nausea—Thiotepa—urinary bladder cancer	0.000108	0.00108	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—urinary bladder cancer	0.000108	0.00108	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—urinary bladder cancer	0.000108	0.00108	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—urinary bladder cancer	0.000107	0.00107	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000106	0.00107	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—urinary bladder cancer	0.000106	0.00107	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—urinary bladder cancer	0.000106	0.00107	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—urinary bladder cancer	0.000105	0.00105	CcSEcCtD
Crizotinib—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000105	0.00105	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000104	0.00105	CcSEcCtD
Crizotinib—CSF1R—lymph node—urinary bladder cancer	0.000104	0.000829	CbGeAlD
Crizotinib—Body temperature increased—Etoposide—urinary bladder cancer	0.000103	0.00104	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—urinary bladder cancer	0.000103	0.00103	CcSEcCtD
Crizotinib—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000103	0.00103	CcSEcCtD
Crizotinib—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000103	0.00103	CcSEcCtD
Crizotinib—CYP3A5—renal system—urinary bladder cancer	0.000102	0.000819	CbGeAlD
Crizotinib—Asthenia—Cisplatin—urinary bladder cancer	0.000102	0.00103	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000102	0.00103	CcSEcCtD
Crizotinib—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000102	0.00102	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000102	0.00102	CcSEcCtD
Crizotinib—Urethral disorder—Epirubicin—urinary bladder cancer	0.000101	0.00101	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.0001	0.00101	CcSEcCtD
Crizotinib—PLK4—Teniposide—Etoposide—urinary bladder cancer	9.96e-05	0.0228	CbGdCrCtD
Crizotinib—Dizziness—Fluorouracil—urinary bladder cancer	9.94e-05	0.000999	CcSEcCtD
Crizotinib—Visual impairment—Epirubicin—urinary bladder cancer	9.93e-05	0.000997	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—urinary bladder cancer	9.92e-05	0.000997	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Epirubicin—urinary bladder cancer	9.89e-05	0.0226	CbGdCrCtD
Crizotinib—Diarrhoea—Cisplatin—urinary bladder cancer	9.75e-05	0.00098	CcSEcCtD
Crizotinib—Vomiting—Gemcitabine—urinary bladder cancer	9.72e-05	0.000977	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—urinary bladder cancer	9.71e-05	0.000975	CcSEcCtD
Crizotinib—Rash—Gemcitabine—urinary bladder cancer	9.64e-05	0.000969	CcSEcCtD
Crizotinib—Dermatitis—Gemcitabine—urinary bladder cancer	9.63e-05	0.000968	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—urinary bladder cancer	9.63e-05	0.000967	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—urinary bladder cancer	9.58e-05	0.000963	CcSEcCtD
Crizotinib—Cardiac disorder—Epirubicin—urinary bladder cancer	9.56e-05	0.00096	CcSEcCtD
Crizotinib—Vomiting—Fluorouracil—urinary bladder cancer	9.56e-05	0.00096	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—urinary bladder cancer	9.49e-05	0.000953	CcSEcCtD
Crizotinib—Rash—Fluorouracil—urinary bladder cancer	9.48e-05	0.000952	CcSEcCtD
Crizotinib—Dermatitis—Fluorouracil—urinary bladder cancer	9.47e-05	0.000951	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	9.42e-05	0.000946	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—urinary bladder cancer	9.39e-05	0.000943	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—urinary bladder cancer	9.39e-05	0.000943	CcSEcCtD
Crizotinib—Asthenia—Etoposide—urinary bladder cancer	9.37e-05	0.000941	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—urinary bladder cancer	9.35e-05	0.000939	CcSEcCtD
Crizotinib—Mediastinal disorder—Epirubicin—urinary bladder cancer	9.29e-05	0.000933	CcSEcCtD
Crizotinib—Arrhythmia—Epirubicin—urinary bladder cancer	9.2e-05	0.000924	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—urinary bladder cancer	9.19e-05	0.000923	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—urinary bladder cancer	9.15e-05	0.0209	CbGdCrCtD
Crizotinib—Nausea—Gemcitabine—urinary bladder cancer	9.08e-05	0.000912	CcSEcCtD
Crizotinib—Vomiting—Cisplatin—urinary bladder cancer	9.06e-05	0.00091	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—urinary bladder cancer	9.03e-05	0.000907	CcSEcCtD
Crizotinib—Rash—Cisplatin—urinary bladder cancer	8.99e-05	0.000903	CcSEcCtD
Crizotinib—Dermatitis—Cisplatin—urinary bladder cancer	8.98e-05	0.000902	CcSEcCtD
Crizotinib—Malnutrition—Epirubicin—urinary bladder cancer	8.97e-05	0.000901	CcSEcCtD
Crizotinib—Diarrhoea—Etoposide—urinary bladder cancer	8.94e-05	0.000897	CcSEcCtD
Crizotinib—Nausea—Fluorouracil—urinary bladder cancer	8.93e-05	0.000897	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—urinary bladder cancer	8.91e-05	0.000895	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—urinary bladder cancer	8.86e-05	0.00089	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—urinary bladder cancer	8.85e-05	0.000889	CcSEcCtD
Crizotinib—Dysgeusia—Epirubicin—urinary bladder cancer	8.78e-05	0.000882	CcSEcCtD
Crizotinib—Dizziness—Etoposide—urinary bladder cancer	8.64e-05	0.000867	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	8.59e-05	0.000863	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—urinary bladder cancer	8.58e-05	0.000862	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—urinary bladder cancer	8.52e-05	0.000855	CcSEcCtD
Crizotinib—Nausea—Cisplatin—urinary bladder cancer	8.47e-05	0.00085	CcSEcCtD
Crizotinib—Vision blurred—Epirubicin—urinary bladder cancer	8.45e-05	0.000849	CcSEcCtD
Crizotinib—Vomiting—Etoposide—urinary bladder cancer	8.3e-05	0.000834	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—urinary bladder cancer	8.3e-05	0.000834	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—urinary bladder cancer	8.29e-05	0.000833	CcSEcCtD
Crizotinib—Rash—Etoposide—urinary bladder cancer	8.23e-05	0.000827	CcSEcCtD
Crizotinib—Dermatitis—Etoposide—urinary bladder cancer	8.23e-05	0.000826	CcSEcCtD
Crizotinib—ABL1—lymph node—urinary bladder cancer	8.19e-05	0.000655	CbGeAlD
Crizotinib—Dysgeusia—Doxorubicin—urinary bladder cancer	8.13e-05	0.000816	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.1e-05	0.000814	CcSEcCtD
Crizotinib—Syncope—Epirubicin—urinary bladder cancer	8.04e-05	0.000808	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—urinary bladder cancer	8.03e-05	0.000806	CcSEcCtD
Crizotinib—ABCB1—prostate gland—urinary bladder cancer	7.97e-05	0.000638	CbGeAlD
Crizotinib—CDK7—Daunorubicin—Epirubicin—urinary bladder cancer	7.97e-05	0.0182	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Epirubicin—urinary bladder cancer	7.97e-05	0.0182	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—urinary bladder cancer	7.97e-05	0.0182	CbGdCrCtD
Crizotinib—Loss of consciousness—Epirubicin—urinary bladder cancer	7.88e-05	0.000792	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—urinary bladder cancer	7.82e-05	0.000786	CcSEcCtD
Crizotinib—AURKA—Teniposide—Etoposide—urinary bladder cancer	7.8e-05	0.0178	CbGdCrCtD
Crizotinib—Infection—Methotrexate—urinary bladder cancer	7.77e-05	0.000781	CcSEcCtD
Crizotinib—Nausea—Etoposide—urinary bladder cancer	7.76e-05	0.000779	CcSEcCtD
Crizotinib—CYP3A4—renal system—urinary bladder cancer	7.68e-05	0.000614	CbGeAlD
Crizotinib—Nervous system disorder—Methotrexate—urinary bladder cancer	7.67e-05	0.00077	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—urinary bladder cancer	7.67e-05	0.00077	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—urinary bladder cancer	7.6e-05	0.000763	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	7.58e-05	0.000762	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—urinary bladder cancer	7.44e-05	0.000748	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—urinary bladder cancer	7.43e-05	0.000746	CcSEcCtD
Crizotinib—CYP3A5—vagina—urinary bladder cancer	7.41e-05	0.000593	CbGeAlD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—urinary bladder cancer	7.37e-05	0.0168	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—urinary bladder cancer	7.37e-05	0.0168	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—urinary bladder cancer	7.37e-05	0.0168	CbGdCrCtD
Crizotinib—Oedema—Epirubicin—urinary bladder cancer	7.32e-05	0.000735	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.29e-05	0.000733	CcSEcCtD
Crizotinib—Infection—Epirubicin—urinary bladder cancer	7.27e-05	0.00073	CcSEcCtD
Crizotinib—Shock—Epirubicin—urinary bladder cancer	7.2e-05	0.000723	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—urinary bladder cancer	7.18e-05	0.000721	CcSEcCtD
Crizotinib—Skin disorder—Epirubicin—urinary bladder cancer	7.11e-05	0.000714	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—urinary bladder cancer	7.02e-05	0.000705	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.02e-05	0.000705	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—urinary bladder cancer	6.97e-05	0.0007	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—urinary bladder cancer	6.89e-05	0.000692	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—urinary bladder cancer	6.8e-05	0.000683	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—urinary bladder cancer	6.77e-05	0.00068	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.75e-05	0.000678	CcSEcCtD
Crizotinib—ABCB1—seminal vesicle—urinary bladder cancer	6.74e-05	0.00054	CbGeAlD
Crizotinib—Fatigue—Methotrexate—urinary bladder cancer	6.74e-05	0.000677	CcSEcCtD
Crizotinib—Infection—Doxorubicin—urinary bladder cancer	6.73e-05	0.000676	CcSEcCtD
Crizotinib—Shock—Doxorubicin—urinary bladder cancer	6.66e-05	0.000669	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.64e-05	0.000667	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—urinary bladder cancer	6.58e-05	0.000661	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—urinary bladder cancer	6.57e-05	0.00066	CcSEcCtD
Crizotinib—Dyspnoea—Epirubicin—urinary bladder cancer	6.53e-05	0.000655	CcSEcCtD
Crizotinib—Dyspepsia—Epirubicin—urinary bladder cancer	6.44e-05	0.000647	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—urinary bladder cancer	6.36e-05	0.000639	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.32e-05	0.000635	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—urinary bladder cancer	6.31e-05	0.000634	CcSEcCtD
Crizotinib—Constipation—Epirubicin—urinary bladder cancer	6.26e-05	0.000629	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—urinary bladder cancer	6.18e-05	0.000621	CcSEcCtD
Crizotinib—CYP3A4—female reproductive system—urinary bladder cancer	6.15e-05	0.000492	CbGeAlD
Crizotinib—Paraesthesia—Doxorubicin—urinary bladder cancer	6.08e-05	0.000611	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—urinary bladder cancer	6.04e-05	0.000607	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—urinary bladder cancer	5.96e-05	0.000599	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—urinary bladder cancer	5.89e-05	0.000591	CcSEcCtD
Crizotinib—ABCB1—epithelium—urinary bladder cancer	5.86e-05	0.000469	CbGeAlD
Crizotinib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.85e-05	0.000587	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—urinary bladder cancer	5.84e-05	0.000587	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—urinary bladder cancer	5.79e-05	0.000582	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—urinary bladder cancer	5.79e-05	0.000581	CcSEcCtD
Crizotinib—Asthenia—Methotrexate—urinary bladder cancer	5.61e-05	0.000564	CcSEcCtD
Crizotinib—ABCB1—renal system—urinary bladder cancer	5.43e-05	0.000435	CbGeAlD
Crizotinib—Body temperature increased—Doxorubicin—urinary bladder cancer	5.35e-05	0.000538	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—urinary bladder cancer	5.35e-05	0.000538	CcSEcCtD
Crizotinib—ABCB1—urethra—urinary bladder cancer	5.34e-05	0.000427	CbGeAlD
Crizotinib—Asthenia—Epirubicin—urinary bladder cancer	5.25e-05	0.000528	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—urinary bladder cancer	5.19e-05	0.0119	CbGdCrCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—urinary bladder cancer	5.19e-05	0.0119	CbGdCrCtD
Crizotinib—Dizziness—Methotrexate—urinary bladder cancer	5.17e-05	0.00052	CcSEcCtD
Crizotinib—Diarrhoea—Epirubicin—urinary bladder cancer	5.01e-05	0.000503	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—urinary bladder cancer	4.97e-05	0.0005	CcSEcCtD
Crizotinib—Rash—Methotrexate—urinary bladder cancer	4.93e-05	0.000495	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—urinary bladder cancer	4.93e-05	0.000495	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—urinary bladder cancer	4.86e-05	0.000488	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—urinary bladder cancer	4.84e-05	0.000486	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—urinary bladder cancer	4.81e-05	0.011	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—urinary bladder cancer	4.81e-05	0.011	CbGdCrCtD
Crizotinib—Vomiting—Epirubicin—urinary bladder cancer	4.65e-05	0.000467	CcSEcCtD
Crizotinib—Nausea—Methotrexate—urinary bladder cancer	4.65e-05	0.000467	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—urinary bladder cancer	4.63e-05	0.000465	CcSEcCtD
Crizotinib—Rash—Epirubicin—urinary bladder cancer	4.62e-05	0.000464	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—urinary bladder cancer	4.61e-05	0.000463	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—urinary bladder cancer	4.48e-05	0.00045	CcSEcCtD
Crizotinib—AURKA—Cytarabine—Gemcitabine—urinary bladder cancer	4.39e-05	0.01	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—urinary bladder cancer	4.37e-05	0.00998	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—urinary bladder cancer	4.37e-05	0.00998	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Epirubicin—urinary bladder cancer	4.37e-05	0.00998	CbGdCrCtD
Crizotinib—ABCB1—female reproductive system—urinary bladder cancer	4.35e-05	0.000348	CbGeAlD
Crizotinib—Nausea—Epirubicin—urinary bladder cancer	4.35e-05	0.000437	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—urinary bladder cancer	4.31e-05	0.000433	CcSEcCtD
Crizotinib—Rash—Doxorubicin—urinary bladder cancer	4.27e-05	0.000429	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—urinary bladder cancer	4.27e-05	0.000429	CcSEcCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—urinary bladder cancer	4.07e-05	0.00929	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—urinary bladder cancer	4.07e-05	0.00929	CbGdCrCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—urinary bladder cancer	4.07e-05	0.00929	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—urinary bladder cancer	4.04e-05	0.00923	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—urinary bladder cancer	4.04e-05	0.00923	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—urinary bladder cancer	4.04e-05	0.00923	CbGdCrCtD
Crizotinib—Nausea—Doxorubicin—urinary bladder cancer	4.02e-05	0.000404	CcSEcCtD
Crizotinib—ABCB1—vagina—urinary bladder cancer	3.94e-05	0.000315	CbGeAlD
Crizotinib—AURKA—Idarubicin—Doxorubicin—urinary bladder cancer	3.76e-05	0.0086	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—urinary bladder cancer	3.76e-05	0.0086	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—urinary bladder cancer	3.76e-05	0.0086	CbGdCrCtD
Crizotinib—ABCB1—lymph node—urinary bladder cancer	2.55e-05	0.000204	CbGeAlD
Crizotinib—PTK2—Signaling Pathways—CCND1—urinary bladder cancer	1.66e-06	1.01e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—urinary bladder cancer	1.66e-06	1.01e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CREBBP—urinary bladder cancer	1.65e-06	1e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.65e-06	1e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—urinary bladder cancer	1.65e-06	1e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCND1—urinary bladder cancer	1.64e-06	9.95e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—urinary bladder cancer	1.64e-06	9.94e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.63e-06	9.91e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.63e-06	9.91e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF1—urinary bladder cancer	1.63e-06	9.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EP300—urinary bladder cancer	1.63e-06	9.88e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CXCL8—urinary bladder cancer	1.62e-06	9.83e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—urinary bladder cancer	1.62e-06	9.83e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—ERBB2—urinary bladder cancer	1.62e-06	9.83e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—urinary bladder cancer	1.61e-06	9.79e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—urinary bladder cancer	1.61e-06	9.77e-06	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—urinary bladder cancer	1.61e-06	9.77e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.61e-06	9.76e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.61e-06	9.75e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PTEN—urinary bladder cancer	1.6e-06	9.74e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MYC—urinary bladder cancer	1.6e-06	9.73e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—KRAS—urinary bladder cancer	1.6e-06	9.69e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—urinary bladder cancer	1.6e-06	9.69e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—urinary bladder cancer	1.59e-06	9.68e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—urinary bladder cancer	1.59e-06	9.66e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGFR3—urinary bladder cancer	1.59e-06	9.65e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—urinary bladder cancer	1.59e-06	9.65e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.58e-06	9.62e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—SRC—urinary bladder cancer	1.58e-06	9.61e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—urinary bladder cancer	1.58e-06	9.61e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PTEN—urinary bladder cancer	1.58e-06	9.6e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—CDKN1A—urinary bladder cancer	1.58e-06	9.59e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTEN—urinary bladder cancer	1.57e-06	9.57e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KRAS—urinary bladder cancer	1.57e-06	9.53e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—urinary bladder cancer	1.57e-06	9.51e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—urinary bladder cancer	1.56e-06	9.5e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.56e-06	9.49e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCND1—urinary bladder cancer	1.55e-06	9.44e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MYC—urinary bladder cancer	1.55e-06	9.43e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB2—urinary bladder cancer	1.55e-06	9.42e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—RHOA—urinary bladder cancer	1.55e-06	9.4e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—urinary bladder cancer	1.55e-06	9.4e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KRAS—urinary bladder cancer	1.55e-06	9.39e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CREBBP—urinary bladder cancer	1.54e-06	9.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ESR1—urinary bladder cancer	1.54e-06	9.38e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.54e-06	9.33e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.53e-06	9.32e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TERT—urinary bladder cancer	1.53e-06	9.31e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EP300—urinary bladder cancer	1.53e-06	9.29e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF1—urinary bladder cancer	1.53e-06	9.27e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—urinary bladder cancer	1.52e-06	9.22e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—urinary bladder cancer	1.52e-06	9.22e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—urinary bladder cancer	1.51e-06	9.19e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—urinary bladder cancer	1.51e-06	9.16e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCND1—urinary bladder cancer	1.51e-06	9.16e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EP300—urinary bladder cancer	1.51e-06	9.16e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.5e-06	9.13e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EP300—urinary bladder cancer	1.5e-06	9.12e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PTEN—urinary bladder cancer	1.5e-06	9.11e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDKN1A—urinary bladder cancer	1.5e-06	9.1e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—urinary bladder cancer	1.5e-06	9.09e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PTEN—urinary bladder cancer	1.49e-06	9.08e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RHOA—urinary bladder cancer	1.49e-06	9.07e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SRC—urinary bladder cancer	1.49e-06	9.03e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—urinary bladder cancer	1.48e-06	9e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—urinary bladder cancer	1.48e-06	9e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—urinary bladder cancer	1.48e-06	8.99e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—urinary bladder cancer	1.47e-06	8.96e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—urinary bladder cancer	1.47e-06	8.93e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SRC—urinary bladder cancer	1.47e-06	8.9e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—urinary bladder cancer	1.46e-06	8.89e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—SRC—urinary bladder cancer	1.46e-06	8.87e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.46e-06	8.86e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PTEN—urinary bladder cancer	1.46e-06	8.84e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.44e-06	8.76e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—urinary bladder cancer	1.43e-06	8.71e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—urinary bladder cancer	1.43e-06	8.71e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB2—urinary bladder cancer	1.43e-06	8.7e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EP300—urinary bladder cancer	1.43e-06	8.69e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EP300—urinary bladder cancer	1.42e-06	8.66e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—urinary bladder cancer	1.42e-06	8.65e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGFR3—urinary bladder cancer	1.41e-06	8.55e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—urinary bladder cancer	1.41e-06	8.54e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—urinary bladder cancer	1.4e-06	8.51e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—urinary bladder cancer	1.4e-06	8.5e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RHOA—urinary bladder cancer	1.4e-06	8.49e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—urinary bladder cancer	1.39e-06	8.47e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—urinary bladder cancer	1.39e-06	8.46e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SRC—urinary bladder cancer	1.39e-06	8.45e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EP300—urinary bladder cancer	1.39e-06	8.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—urinary bladder cancer	1.39e-06	8.42e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—SRC—urinary bladder cancer	1.39e-06	8.42e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1A—urinary bladder cancer	1.38e-06	8.4e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—urinary bladder cancer	1.38e-06	8.4e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTEN—urinary bladder cancer	1.38e-06	8.38e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—urinary bladder cancer	1.37e-06	8.35e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ESR1—urinary bladder cancer	1.37e-06	8.3e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—urinary bladder cancer	1.36e-06	8.24e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CREBBP—urinary bladder cancer	1.35e-06	8.22e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SRC—urinary bladder cancer	1.35e-06	8.2e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.34e-06	8.14e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1—urinary bladder cancer	1.34e-06	8.12e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—urinary bladder cancer	1.33e-06	8.1e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—urinary bladder cancer	1.33e-06	8.09e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1A—urinary bladder cancer	1.33e-06	8.05e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.33e-06	8.05e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PTEN—urinary bladder cancer	1.32e-06	8.04e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EP300—urinary bladder cancer	1.32e-06	7.99e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—urinary bladder cancer	1.31e-06	7.99e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—urinary bladder cancer	1.31e-06	7.98e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—urinary bladder cancer	1.31e-06	7.98e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL8—urinary bladder cancer	1.31e-06	7.96e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—urinary bladder cancer	1.31e-06	7.96e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—urinary bladder cancer	1.31e-06	7.95e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—urinary bladder cancer	1.3e-06	7.91e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—urinary bladder cancer	1.29e-06	7.86e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—urinary bladder cancer	1.28e-06	7.8e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—urinary bladder cancer	1.28e-06	7.78e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—SRC—urinary bladder cancer	1.28e-06	7.77e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—urinary bladder cancer	1.27e-06	7.74e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EP300—urinary bladder cancer	1.26e-06	7.66e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—urinary bladder cancer	1.26e-06	7.64e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—urinary bladder cancer	1.25e-06	7.61e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—urinary bladder cancer	1.25e-06	7.57e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.25e-06	7.56e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.23e-06	7.48e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.23e-06	7.48e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—urinary bladder cancer	1.23e-06	7.48e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.23e-06	7.46e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.23e-06	7.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—urinary bladder cancer	1.23e-06	7.45e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—urinary bladder cancer	1.22e-06	7.44e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RHOA—urinary bladder cancer	1.22e-06	7.43e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—urinary bladder cancer	1.22e-06	7.42e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—urinary bladder cancer	1.22e-06	7.42e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—urinary bladder cancer	1.22e-06	7.41e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—urinary bladder cancer	1.22e-06	7.4e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—urinary bladder cancer	1.22e-06	7.4e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—urinary bladder cancer	1.21e-06	7.38e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—urinary bladder cancer	1.21e-06	7.37e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—urinary bladder cancer	1.21e-06	7.35e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—urinary bladder cancer	1.21e-06	7.35e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CREBBP—urinary bladder cancer	1.2e-06	7.27e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.19e-06	7.23e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—urinary bladder cancer	1.19e-06	7.23e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—urinary bladder cancer	1.19e-06	7.2e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—urinary bladder cancer	1.18e-06	7.19e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—urinary bladder cancer	1.18e-06	7.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—urinary bladder cancer	1.18e-06	7.18e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—urinary bladder cancer	1.18e-06	7.18e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.18e-06	7.16e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—urinary bladder cancer	1.18e-06	7.16e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—urinary bladder cancer	1.17e-06	7.12e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.17e-06	7.1e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—urinary bladder cancer	1.16e-06	7.08e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.16e-06	7.03e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—urinary bladder cancer	1.15e-06	6.99e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—urinary bladder cancer	1.15e-06	6.97e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—urinary bladder cancer	1.15e-06	6.96e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—urinary bladder cancer	1.14e-06	6.94e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—urinary bladder cancer	1.13e-06	6.88e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—urinary bladder cancer	1.12e-06	6.83e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.12e-06	6.82e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—urinary bladder cancer	1.12e-06	6.81e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—urinary bladder cancer	1.12e-06	6.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—urinary bladder cancer	1.11e-06	6.76e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—urinary bladder cancer	1.11e-06	6.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.11e-06	6.72e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—urinary bladder cancer	1.1e-06	6.7e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—urinary bladder cancer	1.09e-06	6.64e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SRC—urinary bladder cancer	1.09e-06	6.64e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.09e-06	6.61e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RHOA—urinary bladder cancer	1.08e-06	6.58e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—urinary bladder cancer	1.08e-06	6.55e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—urinary bladder cancer	1.08e-06	6.53e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—urinary bladder cancer	1.07e-06	6.53e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—urinary bladder cancer	1.06e-06	6.44e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—urinary bladder cancer	1.05e-06	6.39e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—urinary bladder cancer	1.05e-06	6.35e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—urinary bladder cancer	1.03e-06	6.27e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—urinary bladder cancer	1.03e-06	6.24e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—urinary bladder cancer	1.03e-06	6.24e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—urinary bladder cancer	1.02e-06	6.22e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SRC—urinary bladder cancer	1.02e-06	6.21e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—urinary bladder cancer	1.02e-06	6.17e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—urinary bladder cancer	1.01e-06	6.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—urinary bladder cancer	1e-06	6.09e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—urinary bladder cancer	1e-06	6.08e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—urinary bladder cancer	9.93e-07	6.03e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—urinary bladder cancer	9.93e-07	6.03e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.89e-07	6.01e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—urinary bladder cancer	9.79e-07	5.95e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—urinary bladder cancer	9.78e-07	5.94e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—urinary bladder cancer	9.75e-07	5.92e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—urinary bladder cancer	9.72e-07	5.9e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—urinary bladder cancer	9.68e-07	5.88e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—urinary bladder cancer	9.66e-07	5.87e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—urinary bladder cancer	9.58e-07	5.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—urinary bladder cancer	9.51e-07	5.78e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—urinary bladder cancer	9.5e-07	5.77e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—urinary bladder cancer	9.38e-07	5.7e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—urinary bladder cancer	9.21e-07	5.6e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	9.19e-07	5.59e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—urinary bladder cancer	9.17e-07	5.57e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—urinary bladder cancer	9.09e-07	5.52e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—urinary bladder cancer	9.05e-07	5.5e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—urinary bladder cancer	9e-07	5.47e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—urinary bladder cancer	8.96e-07	5.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SRC—urinary bladder cancer	8.96e-07	5.44e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—urinary bladder cancer	8.86e-07	5.38e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.82e-07	5.36e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—urinary bladder cancer	8.63e-07	5.24e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—urinary bladder cancer	8.6e-07	5.23e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—urinary bladder cancer	8.57e-07	5.21e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—urinary bladder cancer	8.55e-07	5.2e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	8.47e-07	5.15e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—urinary bladder cancer	8.47e-07	5.14e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.25e-07	5.01e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—urinary bladder cancer	8.16e-07	4.95e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—urinary bladder cancer	8.04e-07	4.89e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—urinary bladder cancer	8.03e-07	4.88e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—urinary bladder cancer	8.02e-07	4.87e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—urinary bladder cancer	7.97e-07	4.84e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—urinary bladder cancer	7.85e-07	4.77e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—urinary bladder cancer	7.69e-07	4.67e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.67e-07	4.66e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—urinary bladder cancer	7.65e-07	4.65e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.58e-07	4.61e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.58e-07	4.61e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—urinary bladder cancer	7.53e-07	4.57e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—urinary bladder cancer	7.42e-07	4.51e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.26e-07	4.41e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—urinary bladder cancer	7.2e-07	4.37e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.13e-07	4.33e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—urinary bladder cancer	7.11e-07	4.32e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—urinary bladder cancer	6.95e-07	4.22e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.94e-07	4.21e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.7e-07	4.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—urinary bladder cancer	6.59e-07	4.01e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—urinary bladder cancer	6.57e-07	3.99e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—urinary bladder cancer	6.3e-07	3.83e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—urinary bladder cancer	6.05e-07	3.68e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—urinary bladder cancer	5.84e-07	3.55e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—urinary bladder cancer	5.77e-07	3.51e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—urinary bladder cancer	5.58e-07	3.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.43e-07	3.3e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.22e-07	3.17e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.27e-07	2.6e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.73e-07	2.26e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.56e-07	2.16e-06	CbGpPWpGaD
